Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Rand

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Dermatology and Therapy|October 28, 2023
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic DermatitisKim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, et al.
Dermatology and Therapy|January 20, 2024
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic DermatitisKim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 17, 2015
Learning and satisficing: an analysis of sequence effects in health valuationBenjamin M Craig, Shannon K Runge, Kim Rand-Hendriksen, et al.
Dermatology and Therapy|March 4, 2024
Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'"Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, et al.
Pharmacoeconomics - Open|October 8, 2024
Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE StudyAren Fischer, Stephen Mac, Erica Stivelman Freiman, et al.
The Journal of Allergy and Clinical Immunology|June 21, 2022
Normal B-cell ranges in infants: A systematic review and meta-analysisFrancesco Borriello, Noemi Pasquarelli, Lisa Law, et al.
Pharmacoeconomics|August 29, 2025
Developing an EQ-5D-5L Value Set for SingaporeNan Luo, Annushiah Vasan Thakumar, Ling Jie Cheng, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|October 14, 2023
Valuation of EQ-5D-5L health states from cancer patients' perspective: a feasibility studyQingqing Chai, Zhihao Yang, Xiaoyan Liu, et al.
Dermatology and Therapy|December 29, 2025
Letter to the Editor Regarding "Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo Adjusted Indirect Treatment Comparison"Raj Chovatiya, Lucia Seminario-Vidal, Gaia Gallo, et al.
Pharmacoeconomics|December 12, 2018
EQ-5D-5L Valuation for the Malaysian PopulationAsrul Akmal Shafie, Annushiah Vasan Thakumar, Ching Jou Lim, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Dermatology and Therapy|October 28, 2023
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic DermatitisKim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, et al.
Dermatology and Therapy|January 20, 2024
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic DermatitisKim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 17, 2015
Learning and satisficing: an analysis of sequence effects in health valuationBenjamin M Craig, Shannon K Runge, Kim Rand-Hendriksen, et al.
Dermatology and Therapy|March 4, 2024
Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'"Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, et al.
Pharmacoeconomics - Open|October 8, 2024
Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE StudyAren Fischer, Stephen Mac, Erica Stivelman Freiman, et al.
The Journal of Allergy and Clinical Immunology|June 21, 2022
Normal B-cell ranges in infants: A systematic review and meta-analysisFrancesco Borriello, Noemi Pasquarelli, Lisa Law, et al.
Pharmacoeconomics|August 29, 2025
Developing an EQ-5D-5L Value Set for SingaporeNan Luo, Annushiah Vasan Thakumar, Ling Jie Cheng, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|October 14, 2023
Valuation of EQ-5D-5L health states from cancer patients' perspective: a feasibility studyQingqing Chai, Zhihao Yang, Xiaoyan Liu, et al.
Dermatology and Therapy|December 29, 2025
Letter to the Editor Regarding "Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo Adjusted Indirect Treatment Comparison"Raj Chovatiya, Lucia Seminario-Vidal, Gaia Gallo, et al.
Pharmacoeconomics|December 12, 2018
EQ-5D-5L Valuation for the Malaysian PopulationAsrul Akmal Shafie, Annushiah Vasan Thakumar, Ching Jou Lim, et al.
Pageof 9